EGFR-TKIs have been established as standard first-line treatments for EGFR-mutated NSCLC.8 However, acquired resistance to EGFR-TKIs inevitably develops and NSCLC patients ultimately experience disease progression,9–11 highlighting the importance of exploring novel EGFR-TKIs or therapeutic agents exhibiting biological synergy with EGFR-TKIs for advanced EGFR mutated NSCLC.12 The gene discussed is EGFR; the disease is non-small cell lung carcinoma.